Benson 2004.

Methods	ACTG A 5086 trial N=41 Randomized Open label fup: 48 weeks w/o: reported
Participants	Eligibility :‐ VL>10,000 copies/ml CD4:>150 cells/mm3 ART: one virologic failure Baseline CD4 226 cells/mm3 Baseline VL 38,000 cop/ml
Interventions	16 wks STI
Outcomes	STI arm: CD4 increase of + 10 cells/mm3 VL decline ‐0.65 log copies/ml Control arm: CD4 increase of +17.5 cells/mm3 VL decline of ‐1.15 log copies/ml
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate